Evolution of androgen receptor targeted therapy for advanced prostate cancer - PubMed

Review

Evolution of androgen receptor targeted therapy for advanced prostate cancer

Yien Ning Sophia Wong et al. Nat Rev Clin Oncol. 2014 Jun.

Abstract

The discovery of androgen dependence in prostate cancer in 1941 by Huggins and colleagues has remained the backbone for the treatment of this disease. However, although many patients initially respond to androgen depletion therapy, they almost invariably relapse and develop resistance with transition of the disease to a castration-resistant state. Over the past decade, the better understanding of the mechanisms that drive resistance to castration has led to the development of next-generation androgen receptor targeting agents such as abiraterone acetate and enzalutamide. This Review aims to revisit the discovery and evolution of androgen receptor targeting therapeutics for the treatment of advanced-stage prostate cancer over the years and to discuss the upcoming future and challenges in the treatment of this common cancer.

Similar articles

• [ASC-J9 for castration-resistant prostate cancer].

  Yamashita S, Arai Y. Yamashita S, et al. Nihon Rinsho. 2014 Dec;72(12):2126-9. Nihon Rinsho. 2014. PMID: 25518345 Japanese.

• Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches.

  Karantanos T, Corn PG, Thompson TC. Karantanos T, et al. Oncogene. 2013 Dec 5;32(49):5501-11. doi: 10.1038/onc.2013.206. Epub 2013 Jun 10. Oncogene. 2013. PMID: 23752182 Free PMC article. Review.

• Combination Therapy with Androgen Receptor Pathway Inhibitors for Prostate Cancer.

  Blas L, Shiota M. Blas L, et al. Curr Cancer Drug Targets. 2023;23(6):428-432. doi: 10.2174/1568009623666230220121610. Curr Cancer Drug Targets. 2023. PMID: 36803751 No abstract available.

• Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.

  Al Nakouzi N, Le Moulec S, Albigès L, Wang C, Beuzeboc P, Gross-Goupil M, de La Motte Rouge T, Guillot A, Gajda D, Massard C, Gleave M, Fizazi K, Loriot Y. Al Nakouzi N, et al. Eur Urol. 2015 Aug;68(2):228-35. doi: 10.1016/j.eururo.2014.04.015. Epub 2014 May 2. Eur Urol. 2015. PMID: 24837187

• Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.

  Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB. Karantanos T, et al. Eur Urol. 2015 Mar;67(3):470-9. doi: 10.1016/j.eururo.2014.09.049. Epub 2014 Oct 8. Eur Urol. 2015. PMID: 25306226 Free PMC article. Review.

Cited by

• Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer.

  Annala M, Kivinummi K, Tuominen J, Karakurt S, Granberg K, Latonen L, Ylipää A, Sjöblom L, Ruusuvuori P, Saramäki O, Kaukoniemi KM, Yli-Harja O, Vessella RL, Tammela TL, Zhang W, Visakorpi T, Nykter M. Annala M, et al. Oncotarget. 2015 Mar 20;6(8):6235-50. doi: 10.18632/oncotarget.3359. Oncotarget. 2015. PMID: 25749039 Free PMC article.

• Cholinergic signaling via muscarinic M1 receptor confers resistance to docetaxel in prostate cancer.

  Wang J, Wei J, Pu T, Zeng A, Karthikeyan V, Bechtold B, Vo K, Chen J, Lin TP, Chang AP, Corey E, Puhr M, Klocker H, Culig Z, Bland T, Wu BJ. Wang J, et al. Cell Rep Med. 2024 Feb 20;5(2):101388. doi: 10.1016/j.xcrm.2023.101388. Epub 2024 Jan 22. Cell Rep Med. 2024. PMID: 38262412 Free PMC article.

• The Role of Cancer-Associated Fibroblasts in Prostate Cancer Tumorigenesis.

  Bonollo F, Thalmann GN, Kruithof-de Julio M, Karkampouna S. Bonollo F, et al. Cancers (Basel). 2020 Jul 13;12(7):1887. doi: 10.3390/cancers12071887. Cancers (Basel). 2020. PMID: 32668821 Free PMC article. Review.

• PRKAR2B-HIF-1α loop promotes aerobic glycolysis and tumour growth in prostate cancer.

  Xia L, Sun J, Xie S, Chi C, Zhu Y, Pan J, Dong B, Huang Y, Xia W, Sha J, Xue W. Xia L, et al. Cell Prolif. 2020 Nov;53(11):e12918. doi: 10.1111/cpr.12918. Epub 2020 Oct 7. Cell Prolif. 2020. PMID: 33025691 Free PMC article.

• Systematic in vitro analysis of therapy resistance in glioblastoma cell lines by integration of clonogenic survival data with multi-level molecular data.

  Schnöller LE, Piehlmaier D, Weber P, Brix N, Fleischmann DF, Nieto AE, Selmansberger M, Heider T, Hess J, Niyazi M, Belka C, Lauber K, Unger K, Orth M. Schnöller LE, et al. Radiat Oncol. 2023 Mar 11;18(1):51. doi: 10.1186/s13014-023-02241-4. Radiat Oncol. 2023. PMID: 36906590 Free PMC article.

References

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database
  • scite Smart Citations

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal